Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.

Murdock HM, Kim HT, Hambley B, Vachhani P, Denlinger N, Gier SH, Cho C, Perales MA, Koreth J, Ho VT, Soiffer RJ, McCurdy SR, Carroll M, Vasu S, Wang ES, Gondek LP, Devine S, Alyea EP, Gibson CJ, Lindsley RC.

Blood. 2019 Nov 13;134(Supplement_1):48. doi: 10.1182/blood-2019-125967.

PMID:
31724009
2.

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.

Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2019 Oct 31. pii: S1083-8791(19)30706-2. doi: 10.1016/j.bbmt.2019.10.024. [Epub ahead of print]

PMID:
31678537
3.

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.

DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen YB, Soiffer RJ, Antin JH, Ballen KK, Cutler CS.

Bone Marrow Transplant. 2019 Oct 15. doi: 10.1038/s41409-019-0715-x. [Epub ahead of print]

PMID:
31616065
4.

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J.

Blood Adv. 2019 Sep 10;3(17):2550-2561. doi: 10.1182/bloodadvances.2019000631.

5.

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL.

Blood Adv. 2019 Jul 23;3(14):2199-2204. doi: 10.1182/bloodadvances.2019000445.

6.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J.

Blood Adv. 2019 Apr 9;3(7):984-994. doi: 10.1182/bloodadvances.2018027474.

7.

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J.

Blood Adv. 2019 Apr 9;3(7):969-979. doi: 10.1182/bloodadvances.2018029124.

8.

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.

Chapuy CI, Kaufman RM, Alyea EP, Connors JM.

N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438. Erratum in: N Engl J Med. 2019 Jan 17;380(3):302.

PMID:
30403942
9.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

10.

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2019 Jan;25(1):137-144. doi: 10.1016/j.bbmt.2018.07.039. Epub 2018 Aug 3.

PMID:
30081073
11.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M, Johnston L, McGuirk J, Shea TC, Jagasia M, Shaughnessy PJ, Reynolds CG, Fields M, Alyea EP, Ho VT, Glavin F, Dipersio JF, Westervelt P, Ritz J, Soiffer RJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2216-2223. doi: 10.1016/j.bbmt.2018.07.002. Epub 2018 Jul 10.

12.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK.

Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3.

13.

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.

Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16.

14.

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

Nahas MR, Soiffer RJ, Kim HT, Alyea EP 3rd, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J.

Blood. 2018 Jun 21;131(25):2836-2845. doi: 10.1182/blood-2017-05-780239. Epub 2018 Mar 16.

PMID:
29549175
15.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P.

Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.

16.

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.

Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.

Haematologica. 2018 Mar;103(3):522-530. doi: 10.3324/haematol.2017.176859. Epub 2018 Jan 11.

17.

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.

Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ.

Blood Adv. 2017 Nov 14;1(24):2269-2279. doi: 10.1182/bloodadvances.2017009084. eCollection 2017 Nov 14.

18.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

19.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Blood. 2017 Dec 28;130(26):2889-2899. doi: 10.1182/blood-2017-08-801001. Epub 2017 Nov 14.

20.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB.

J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.

PMID:
29040031
21.

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation.

Sultan AS, Zimering Y, Petruzziello G, Alyea EP 3rd, Antin JH, Soiffer RJ, Ho VT, Sonis ST, Woo SB, Marty FM, Treister NS.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):253-260. doi: 10.1016/j.oooo.2017.06.003. Epub 2017 Jun 16.

PMID:
28823316
22.

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.

Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr.

Eur J Heart Fail. 2017 May;19(5):682-685. doi: 10.1002/ejhf.806. No abstract available.

23.

Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias.

Gibson CJ, Kennedy JA, Nikiforow S, Kuo FC, Alyea EP, Ho V, Ritz J, Soiffer R, Antin JH, Lindsley RC.

Blood. 2017 Jul 6;130(1):91-94. doi: 10.1182/blood-2017-01-764951. Epub 2017 Apr 26. No abstract available.

24.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME.

J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.

25.

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J.

Haematologica. 2017 Jul;102(7):1185-1191. doi: 10.3324/haematol.2017.164012. Epub 2017 Mar 24.

26.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.

Blood. 2017 Apr 13;129(15):2186-2197. doi: 10.1182/blood-2016-09-741629. Epub 2017 Feb 1.

27.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL.

J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.

28.

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.

Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP 3rd, Ritz J, Soiffer RJ, Antin JH, Dey B, McAfee S, Chen YB, Spitzer T, Avigan D, Cutler CS, Ballen K.

Cytotherapy. 2017 Feb;19(2):272-284. doi: 10.1016/j.jcyt.2016.10.016. Epub 2016 Dec 9.

PMID:
27939176
29.

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J, Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, Blazar BR, Lacerda JF, Soiffer RJ, Ritz J.

JCI Insight. 2016 Nov 3;1(18):e89278. doi: 10.1172/jci.insight.89278.

30.

Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival.

Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP 3rd, Glotzbecker B.

Biol Blood Marrow Transplant. 2017 Jan;23(1):113-118. doi: 10.1016/j.bbmt.2016.10.012. Epub 2016 Oct 24.

31.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB.

Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.

32.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

33.

Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.

Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P.

Br J Haematol. 2016 Dec;175(5):841-850. doi: 10.1111/bjh.14311. Epub 2016 Oct 6.

34.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.

Treister N, Li S, Kim H, Lerman M, Sultan A, Alyea EP, Armand P, Cutler C, Ho V, Koreth J, Antin JH, Soiffer R.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2084-2091. doi: 10.1016/j.bbmt.2016.08.020. Epub 2016 Aug 30.

35.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ; Leukemia and Lymphoma Society Blood Cancer Research Partnership.

N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.

36.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP 3rd, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J.

Haematologica. 2016 Oct;101(10):1251-1259. Epub 2016 Jun 27.

37.

Graft-Versus-Host Disease Prevention: Corticosteroids Revisited.

Alyea EP.

J Clin Oncol. 2016 Jun 1;34(16):1836-7. doi: 10.1200/JCO.2015.66.0902. Epub 2016 Apr 18. No abstract available.

PMID:
27091715
38.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ.

Blood. 2016 Jul 7;128(1):130-7. doi: 10.1182/blood-2016-02-702852. Epub 2016 Apr 12.

39.

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J.

Blood. 2016 May 19;127(20):2489-97. doi: 10.1182/blood-2015-12-688895. Epub 2016 Mar 4.

40.

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.

Martin PS, Li S, Nikiforow S, Alyea EP 3rd, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ.

Haematologica. 2016 Apr;101(4):499-505. doi: 10.3324/haematol.2015.134841. Epub 2016 Jan 14.

41.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen YB.

Biol Blood Marrow Transplant. 2016 May;22(5):910-8. doi: 10.1016/j.bbmt.2015.12.024. Epub 2015 Dec 31.

42.

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.

Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH.

Br J Haematol. 2016 Apr;173(1):96-104. doi: 10.1111/bjh.13931. Epub 2016 Jan 5.

43.

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, Whangbo J, Nikiforow S, Cutler CS, Koreth J, Ho VT, Armand P, Antin JH, Alyea EP, Lacerda JF, Soiffer RJ, Ritz J.

Blood. 2016 Feb 4;127(5):646-57. doi: 10.1182/blood-2015-10-672345. Epub 2015 Dec 15.

44.

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP.

J Clin Oncol. 2015 Dec 10;33(35):4167-75. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2.

45.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation.

Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ.

Haematologica. 2015 Sep;100(9):1222-7. doi: 10.3324/haematol.2015.129650. Epub 2015 Jun 18.

46.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.

Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1907-13. doi: 10.1016/j.bbmt.2015.05.027. Epub 2015 Jun 6.

47.

Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions.

Nikiforow S, Alyea EP.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):570-5. doi: 10.1182/asheducation-2014.1.570. Epub 2014 Nov 18. Review.

PMID:
25696913
48.

The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT.

Yolin-Raley DS, Dagogo-Jack I, Niell HB, Soiffer RJ, Antin JH, Alyea EP 3rd, Glotzbecker BE.

J Natl Compr Canc Netw. 2015 Feb;13(2):184-9.

PMID:
25691611
49.

The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.

Davids MS, Alyea EP.

Curr Hematol Malig Rep. 2015 Mar;10(1):18-27. doi: 10.1007/s11899-014-0247-9. Review.

PMID:
25682168
50.

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho VT.

Biol Blood Marrow Transplant. 2015 May;21(5):873-80. doi: 10.1016/j.bbmt.2015.01.019. Epub 2015 Jan 23.

Supplemental Content

Loading ...
Support Center